Flyrcado™ : A Breakthrough In Cardiac PET Imaging For Coronary Artery Disease
In a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select U.S. markets since early...
0 Comments 0 Shares 458 Views 0 Reviews
Sponsored

Trade with the best

aking Exness the first name that comes to mind when people think about brokers or trading. We’re putting our traders first, not only with trading conditions, but also with the overall...

Sponsored
Bundas24 https://www.bundas24.com